Compared with the approved CD19-targeted therapies such as CAR-T cells and TCEs, TriBAFF/CD3/ABDCon exhibited markedly superior efficacy in a heterogeneous immune escape model of B-ALL and outperformed Blinatumomab and Tisagenlecleucel. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.